Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2021.Mar.12

OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, Adagloxad Simolenin, to the drug administrations of Mexico

2021.Feb.23

OBI licensed “OBI-858 Novel Botulinum Toxin Preparation” Intellectual Property Right of Global Aesthetic Medicine to OBIGEN Pharma, Inc.

2021.Feb.17

OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, Adagloxad Simolenin, to the drug administrations in Argentina, Brazil, and South Africa

2021.Jan.26

Mr. Michael Chang and five other executives received an acquittal for insider trading case at second instance by Taiwan High Court

2021.Jan.06

OBI Pharma Inc. to attend the 39th Annual J.P. Morgan Healthcare Conference

2020.Dec.30

OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (Announcement of base day and trading counterparty)

2020.Dec.25

The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by National Medical Products Administration (NMPA) to proceed Phase III human clinical study

2020.Dec.14

OBI Pharma Inc. to attend Investor Conference hosted by Masterlink Securities

2020.Dec.04

OBI licensed the Intellectual Property Right of Global Aesthetic Medicine to a designated company

2020.Nov.27

OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (supplement base date)

News

Latest News

Events

Latest events